Efficacy and toxicity of KRAS^G12C inhibitors in advanced solid tumors: a meta-analysis.

ABSTRACT:

Background

The efficacy and toxicity of KRAS^G12C inhibitors were evaluated for advanced solid tumors in several studies; however, the results were not fully consistent.

Methods

Clinical trials evaluating KRAS^G12C inhibitors for advanced solid tumors were searched from PubMed, Embase, and Cochrane Library online databases up to 31st December 2023. The characteristics of the studies and the results of objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) rate, overall survival (OS) rate, and treatment-related adverse events (trAEs) were extracted.

Results

Ten studies with 925 heavily pretreated advanced patients harboring KRAS^G12C mutation were included. For total populatio

SUBMITTER: Dang S 

PROVIDER: S-EPMC11251097 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature